- Home
- SMBK vs CRVS Comparison
SMBK vs CRVS Comparison
Compare SMBK & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SMBK | CRVS |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 636.5M | 634.0M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | SMBK | CRVS |
|---|---|---|
| Price | $38.02 | $7.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $38.63 | $13.75 |
| AVG Volume (30 Days) | 109.8K | ★ 1.6M |
| Earning Date | 01-20-2026 | 11-04-2025 |
| Dividend Yield | ★ 0.84% | N/A |
| EPS Growth | ★ 41.99 | N/A |
| EPS | ★ 2.74 | N/A |
| Revenue | ★ $188,204,000.00 | N/A |
| Revenue This Year | $22.00 | N/A |
| Revenue Next Year | $9.67 | N/A |
| P/E Ratio | $13.97 | ★ N/A |
| Revenue Growth | ★ 18.22 | N/A |
| 52 Week Low | $26.31 | $2.54 |
| 52 Week High | $40.08 | $9.60 |
Technical Indicators
Market Signals| Indicator | SMBK | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 52.34 | 39.21 |
| Support Level | $38.40 | $7.34 |
| Resistance Level | $39.86 | $8.00 |
| Average True Range (ATR) | 0.89 | 0.53 |
| MACD | -0.11 | -0.15 |
| Stochastic Oscillator | 34.24 | 6.19 |
Price Performance
Historical ComparisonAbout SMBK SmartFinancial Inc.
SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).